33422-35-4

Basic information

• Product Name: ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE
• Synonyms: TIMTEC-BB SBB010112;ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE;ETHYL 2-(3-OXOPIPERAZIN-2-YL)ACETATE;ETHYL (3-OXOPIPERAZIN-2-YL)ACETATE;BUTTPARK 32\06-70;(3-OXO-PIPERAZIN-2-YL)-ACETIC ACID ETHYL ESTER;AKOS BC-0605;AKOS BBB/039
• CAS NO: 33422-35-4
• Molecular Formula: C₈H₁₄N₂O₃
• Molecular Weight: 186.21
• Product Categories: pharmacetical;Esters;Pyrans, Piperidines &Piperazines;CHIRAL CHEMICALS;Pyrans, Piperidines & Piperazines
• Mol File: 33422-35-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 110-111°C
• Boiling Point: 360.647 °C at 760 mmHg
• Flash Point: 171.913 °C
• Appearance: /
• Density: 1.101 g/cm³
• Vapor Pressure: 2.19E-05mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 15.06±0.40(Predicted)
• CAS DataBase Reference: ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE(33422-35-4)
• EPA Substance Registry System: ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE(33422-35-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 33422-35-4(Hazardous Substances Data)

Usage

General Description

ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE, also known as EOPA, is a chemical compound with the molecular formula C9H14N2O3. It is a derivative of piperazine and is commonly used in pharmaceutical research and development as a precursor in the synthesis of various pharmaceuticals. EOPA has been found to exhibit antiviral, antibacterial, and antifungal properties, making it a valuable component in the development of new drugs to combat infections. Additionally, it has been researched for its potential use in the treatment of neurological disorders and as an anti-inflammatory agent. Due to its diverse range of biological activities, ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is considered to be a valuable and versatile chemical in the field of medicinal chemistry.

InChI:InChI=1/C8H14N2O3/c1-2-13-7(11)5-6-8(12)10-4-3-9-6/h6,9H,2-5H2,1H3,(H,10,12)/p+1/t6-/m1/s1

Upstream product

• 107-15-3 ethylenediamine 
• 141-05-9 Diethyl maleate 
• 623-91-6 diethyl Fumarate 

Downstream Products

• 129355-67-5 [1-(2,6-Difluoro-benzoyl)-3-oxo-piperazin-2-yl]-acetic acid ethyl ester 
• 129355-68-6 [3-Oxo-1-(2-trifluoromethyl-benzoyl)-piperazin-2-yl]-acetic acid ethyl ester 
• 129355-64-2 1-bromoacetyl-3-oxo-1,4-piperazine-2-acetic acid ethyl ester 
• 3388-79-2 2-(2-hydroxyethyl)piperazine 
• 936940-62-4 3-(2-hydroxyethyl)piperazin-2-one 
• 168160-77-8 t-butyl (RS)-2-ethoxycarbonylmethyl-3-oxo-piperazine-1-carboxylate 
• 917572-18-0 ethyl {1-[1-(diphenylmethyl)azetidin-3-yl]-3-oxopiperazin-2-yl}acetate 

Relevant articles and documents

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula I wherein D, E and G are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the sam